CU20170078A7 - DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER - Google Patents

DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER

Info

Publication number
CU20170078A7
CU20170078A7 CUP2017000078A CU20170078A CU20170078A7 CU 20170078 A7 CU20170078 A7 CU 20170078A7 CU P2017000078 A CUP2017000078 A CU P2017000078A CU 20170078 A CU20170078 A CU 20170078A CU 20170078 A7 CU20170078 A7 CU 20170078A7
Authority
CU
Cuba
Prior art keywords
phenyl
inappropriate cellular
propanamide
triazolo
useful
Prior art date
Application number
CUP2017000078A
Other languages
English (en)
Spanish (es)
Inventor
Ursula Krenz
Dr Hans-Georg Lerchen
Dr Philip Lienau
Dr Ulrich Lücking
Dr Volker Schulze
Dr Gerhard Siemeister
Dr Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170078A7 publication Critical patent/CU20170078A7/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CUP2017000078A 2014-12-09 2015-12-07 DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER CU20170078A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09
PCT/EP2015/078871 WO2016091825A1 (fr) 2014-12-09 2015-12-07 Composés pour le traitement d'un cancer

Publications (1)

Publication Number Publication Date
CU20170078A7 true CU20170078A7 (es) 2017-10-05

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000078A CU20170078A7 (es) 2014-12-09 2015-12-07 DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER

Country Status (27)

Country Link
US (1) US20170342064A1 (fr)
EP (1) EP3230285A1 (fr)
JP (1) JP2017537116A (fr)
KR (1) KR20170088872A (fr)
CN (1) CN107001376A (fr)
AR (1) AR102947A1 (fr)
AU (1) AU2015359593A1 (fr)
BR (1) BR112017012317A2 (fr)
CA (1) CA2969902A1 (fr)
CO (1) CO2017005741A2 (fr)
CR (1) CR20170243A (fr)
CU (1) CU20170078A7 (fr)
DO (1) DOP2017000136A (fr)
EA (1) EA201791264A1 (fr)
EC (1) ECSP17036251A (fr)
IL (1) IL252237A0 (fr)
MA (1) MA41136A (fr)
MX (1) MX2017007655A (fr)
NI (1) NI201700072A (fr)
PE (1) PE20170927A1 (fr)
PH (1) PH12017501063A1 (fr)
SG (1) SG11201704684PA (fr)
TN (1) TN2017000241A1 (fr)
TW (1) TW201625565A (fr)
UY (1) UY36421A (fr)
WO (1) WO2016091825A1 (fr)
ZA (1) ZA201704589B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917467A (zh) * 2021-01-22 2023-10-20 渤健马萨诸塞州股份有限公司 用以增加重组病毒载体滴度的微管去稳定剂添加剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645031A1 (fr) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Composes de promedicament de pyrrolotriazine aniline utiles en tant qu'inhibiteurs de la kinase
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
PE20160156A1 (es) * 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas

Also Published As

Publication number Publication date
BR112017012317A2 (pt) 2018-04-24
MX2017007655A (es) 2017-10-11
UY36421A (es) 2016-06-30
PE20170927A1 (es) 2017-07-13
IL252237A0 (en) 2017-07-31
JP2017537116A (ja) 2017-12-14
CA2969902A1 (fr) 2016-06-16
ZA201704589B (en) 2019-02-27
AU2015359593A1 (en) 2017-06-08
ECSP17036251A (es) 2017-06-30
WO2016091825A1 (fr) 2016-06-16
TW201625565A (zh) 2016-07-16
CO2017005741A2 (es) 2017-08-31
US20170342064A1 (en) 2017-11-30
CR20170243A (es) 2017-07-26
MA41136A (fr) 2017-10-17
EA201791264A1 (ru) 2017-12-29
PH12017501063A1 (en) 2017-12-11
NI201700072A (es) 2017-07-17
KR20170088872A (ko) 2017-08-02
EP3230285A1 (fr) 2017-10-18
SG11201704684PA (en) 2017-07-28
CN107001376A (zh) 2017-08-01
DOP2017000136A (es) 2017-08-31
AR102947A1 (es) 2017-04-05
TN2017000241A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
HUE059624T2 (hu) N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CU20170029A7 (es) Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
MX2021009673A (es) Moduladores de ror-gamma.
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
EA201691421A1 (ru) Гетероарилы и их применение
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2017000792A1 (es) Derivados del ácido borónico
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018008362A (es) Derivados de quinolin-2-ona.
CO2019008110A2 (es) Activador de nrf2
MX388612B (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.